Cablivi
Cablivi ingredients
| Active ingredient | Strength |
|---|---|
| Caplacizumab | see label |
What Cablivi is used for
The FDA lists the approved uses on the official label (below). In the EU, caplacizumab is approved as Cablivi for:
Cablivi is indicated for the treatment of adults experiencing an episode of acquired thrombotic thrombocytopenic purpura (aTTP), in conjunction with plasma exchange and immunosuppression.
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Cablivi
- Generic name
- Caplacizumab
- Made by
- Genzyme Corporation
- Forms
- Kit
- FDA approval
- Biologic licence (BLA) BLA761112
- On the US market since
- 2019
Official information
- Cablivi prescribing information (FDA label) on DailyMed
- MedlinePlus drug information (search for Caplacizumab)
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Cablivi?
Cablivi (Caplacizumab) is a specialist medicine made by Genzyme Corporation, approved by the US FDA.
What are the ingredients of Cablivi?
Cablivi contains Caplacizumab.
Is Cablivi approved in Europe?
The same active substance is approved in the EU as Cablivi.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA